Additive Anti-inflammatory Action for Aortopathy & Arteriopathy (Rosuvastatin) I
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
Acute Aortic Syndrome (AAS)/Aortic Aneurysm is a common feature of aortic wall events,
including aortic dissection, intramural hematoma, aortic ulceration and aortic trauma, and
occurs in up to 35 cases per 100,000 cases per year between the ages of 65 and 75 years.
Increased levels of the inflammatory biomarker high-sensitivity C-reactive protein predict
cardiovascular events. Since statins lower levels of high-sensitivity C-reactive protein as
well as cholesterol, the authors hypothesized that people with acute aortic syndrome but
without hyperlipidemia might benefit from statin treatment.